• 1
    Ries L, Smith M, Gurney J, et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute; 1999.
  • 2
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790.
  • 3
    Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-2011.
  • 4
    Bhatia S, Landier W, Robison L. Late effects of childhood cancer therapy. In: DeVitaV, HellmanS, RosenbergS, eds. Progress in Oncology 2002. Sudbury, MA: Jone and Barlett Publications; 2003: 171-201.
  • 5
    Nagarajan R, Neglia JP, Clohisy DR, Robison LL. Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol. 2002; 20: 4493-4501.
  • 6
    Robison L, Mertens A, Boice JD, et al. Study design and cohort characteristics of the childhood cancer survivor study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002; 38: 229-239.
  • 7
    Mertens AC, Walls RS, Taylor L, et al. Characteristics of childhood cancer survivors predicted their successful tracing. J Clin Epidemiol. 2004; 57: 933-944.
  • 8
    Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008; 100: 1368-1379.
  • 9
    Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in 5-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001; 93: 618-629.
  • 10
    Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999; 340: 351-357.
  • 11
    Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987; 317: 588-593.
  • 12
    Percy CL, Van Holten V, Muir CS. International Classification of Diseases for Oncology. 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
  • 13
    Kramarova E, Stiller CA. The international classification of childhood cancer. Int J Cancer. 1996; 68: 759-765.
  • 14
    Cancer Therapy Evaluations Program. Common Terminology Criteria for Adverse Events. Bethesda, MD: National Cancer Institute; 2003.
  • 15
    Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355: 1572-1582.
  • 16
    Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA. 2003; 290: 1583-1592.
  • 17
    Derogatis L. Brief Symptom Inventory (BSI) 18: Administration, Scoring, and Procedures Manual. Minneapolis, MN: National Computer Systems; 2000.
  • 18
    Zabora J, BrintzenhofeSzoc K, Jacobsen P, et al. A new psychosocial screening instrument for use with cancer patients. Psychosomatics. 2001; 42: 241-246.
  • 19
    Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta, GA: US Department of Human Health Services; 1993.
  • 20
    Centers for Disease Control and Prevention. National Health Interview Survey. Atlanta, GA: US Department of Human Health Services; 1993.
  • 21
    Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol II. The Design and Analysis of Cohort Studies. New York, NY: International Agency for Research on Cancer; 1987.
  • 22
    Clayton D, Hills M. Statistical Models in Epidemiology. New York, NY: Oxford University Press, 1993.
  • 23
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database. November 2008 submission. Bethesda, MD: National Cancer Institute; 2009.
  • 24
    Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
  • 25
    Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009; 27: 2328-2338.
  • 26
    Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005; 23: 559-568.
  • 27
    Goldsby R, Burke C, Nagarajan R, et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort. Cancer. 2008; 113: 2597-2604.
  • 28
    Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer. 2002; 95: 1728-1734.
  • 29
    Bacci G, Ferrari C, Longhi A, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol. 2006; 28: 774-780.
  • 30
    Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet. 2003; 11: 611-618.
  • 31
    Pratt CB, Meyer WH, Luo X, et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer. 1997; 80: 960-965.
  • 32
    Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004; 26: 649-655.
  • 33
    Stohr W, Langer T, Kremers A, et al. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest. 2005; 23: 201-207.
  • 34
    van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006; 42: 3191-3198.
  • 35
    Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997; 15: 61-68.